Participating Faculty: Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement - Implications for Managed Care

Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement: Implications for Managed Care

The information presented in this supplement to The American Journal of Managed Care is based upon the conclusions and insights derived from a roundtable discussion, which identified means of overcoming barriers to improved outcomes for patients who have undergone surgery for total knee replacement (TKR) or total hip replacement (THR), and who are, consequently, at risk for venous thromboembolism (VTE). The diversity of the assembled healthcare professionals allowed for a wide-ranging discussion of clinical, institutional, and systemic approaches.

The roundtable and this publication were funded by Janssen Pharmaceuticals, Inc.; which included honoraria paid to the faculty members.

Faculty

Robert P. Navarro, PharmD (Moderator)

Clinical Professor

University of Florida—College of Pharmacy

Gainesville, Florida

James E. Barr, MD

Medical Director

Central Jersey Physician Network

Flemington, New Jersey

Karen Faubus, RN, BSN

Director

Clinical Pharmacy Services

Spur, Texas

Aman D. Sabharwal, MD, CPHM

Quality & Safety, and Revenue Cycle Management

Jackson Health System

Assistant Professor of Clinical Medicine

Florida International University College of Medicine

Fort Lauderdale, Florida

Electa Stern, PharmD

Clinical Supervisor, Pharmacy

Sharp Grossmont Hospital

La Mesa, California

Kevin Unger, MBA/MSHA, CHE

President and CEO

Poudre Valley Hospital

Fort Collins, Colorado

Faculty Disclosures

These faculty members have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

James E. Barr, MD

Consultant: Johnson & Johnson

Karen Faubus, RN, BSN

Advisory board/consultant/honoraria: Janssen Pharmaceuticals, Inc

Aman D. Sabharwal, MD, CPHM

Advisory board/consultant: Janssen Pharmaceuticals, Inc

Electa Stern, PharmD

Advisory board/consultant: Boehringer Ingelheim

Kevin Unger, MBA/MSHA, CHE

Advisory board/honoraria: Janssen Pharmaceuticals, Inc

The following participant has nothing to disclose relevant to the content of this supplement:

Robert P. Navarro, PharmD

This supplement was supported by Janssen Pharmaceuticals, Inc.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Publisher’s Note

The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Supplement Policy Statement

Standards for Supplements to The American Journal of Managed Care

All supplements to The American Journal of Managed Care are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All Journal supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to The American Journal of Managed Care will:

1. Be reviewed by at least one independent expert from a recognized academic medical institution.
2. Disclose the source of funding in at least one prominent place.
3. Disclose any existence of financial interests of supplement contributors to the funding organization.
4. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
5. Be up-to-date, reflecting the current (as of date of publication) standard of care.
6. Be visually distinct from The American Journal of Managed Care.
7. Publish information that is substantially different in form and content from that of the accompanying edition of The American Journal of Managed Care.
8. Prohibit excessive remuneration for contributors and reviewers.
9. Carry no advertising.

Download PDF: Participating Faculty: Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement - Implications for Managed Care